Covid-19: Pfizer’s paxlovid is 89% effective in patients at risk of serious illness, company reports

  title={Covid-19: Pfizer’s paxlovid is 89\% effective in patients at risk of serious illness, company reports},
  author={Elisabeth Mahase},
In the study, trial participants were randomised 1:1, with half receiving paxlovid and the other half receiving a placebo orally every 12 hours for five days. Of those who were treated within three days of symptom onset, 0.8% (3/389) of patients who received paxlovid were admitted to hospital up to day 28 after randomisation, with no deaths. In comparison, 7% (27/385) of patients who received placebo were admitted, with seven deaths. The statistical significance of these results was reported as… 

The discovery of PAXLOVID in Covid-19 treatment

  • Shirley He
  • Medicine
    Highlights in Science, Engineering and Technology
  • 2022
PAXLOVID which is the latest oral drug in the world had high absorbance in the human body, safety and efficiency, and the data supported sufficient evidence that PAXLOVIDs in emergency was supported.

The effectiveness of Paxlovid treatment in long-term care facilities in South Korea during the outbreak of the Omicron variant of SARS-CoV-2.

Patients given Paxlovid showed a lower rate of severe illness or death and alower fatality rate than those who did not receive Paxlovin and patients who received 3 doses of the vaccine had a lower Fatality rate.

Effectiveness of Paxlovid in Reducing Severe Coronavirus Disease 2019 and Mortality in High-Risk Patients

Paxlovid appears to be more effective in older patients, immunosuppressed patients, and patients with underlying neurological or cardiovascular disease and in real-life settings, Paxlovid is highly effective in reducing the risk of severe COVID-19 or mortality.

The Use of Mebendazole in COVID-19 Patients: An Observational Retrospective Single Center Study

The use of mebendazole in COVID-19 patients was associated with shorter hospitalizations in the inpatient cohort and shorter durations of symptom resolution in the outpatient cohort, and the findings are hypothesis-generating and preclude drawing conclusions about clinical efficacy.

A randomized controlled trial to evaluate outcomes with Aggrenox in patients with SARS-CoV-2 infection

In this study of hospitalized patients with COVID-19, while the outcomes of COVID illness severity, odds of mortality, and chance of respiratory failure were better in the Aggrenox group compared to standard of care alone, the data did not reach statistical significance to support the standard use of adjuvant Agg Renox in such patients.

Safety and Efficacy of Paxlovid Against Omicron Variants of Coronavirus Disease 2019 in Elderly Patients

The use of Paxlovid in elderly patients may promote recovery from COVID-19 and reduce the viral load without adverse events.

The Effect of Nitazoxanide on the Clinical Outcomes in Patients with COVID-19: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Compared with placebo, nitazoxanide was effective in expediting viral clearance and decreasing oxygen requirements, however, there was no difference between nitazxanide and placebo regarding clinical response, all-cause mortality, and intensive care unit admission, and more large-scale studies are still needed to ascertain the clinical applicability of nitazOxanide in COVID-19.

Efficacy and safety of ivermectin in patients with mild and moderate COVID-19: A randomized controlled trial

Among adult hospitalized patients with moderate to severe COVID-19, there was no significant relationship between the administration of ivermectin single dose in a five-day course and clinical improvement, and mortality of the participants.

Phamrmacoligical Therapies for COVID-19: A Comprehensive Review from 2022 Updated Nih, IDSA and ICMR Guidelines

This review article gives a comprehensive update on various pharmacological therapies in the light of recently published standard treatment guidelines based on large clinical trials for the treatment of COVID-19.

Real-World Effectiveness and Optimal Dosage of Favipiravir for Treatment of COVID-19: Results from a Multicenter Observational Study in Thailand

The study reports the promising effectiveness of favipiravir for treating COVID-19 patients and identifies three poor prognostic factors for Day-7 clinical improvement: older age, high baseline NEWS2 score, and low loading dose.


Covid-19: UK becomes first country to authorise antiviral molnupiravir

The UK’s medicines regulator has issued temporary authorisation of the antiviral drug molnupiravir for the treatment of mild to moderate covid-19 in adults with at least one risk factor for severe